Glenmark Pharmaceuticals’ subsidiary -- Glenmark Pharmaceuticals Inc., USA (Glenmark) has received tentative approval by United States Food & Drug Administration (USFDA) for Clindamycin Phosphate Foam, 1%, a generic version of EVOCLIN Foam, 1%, of Mylan Pharmaceuticals Inc.
According to IQVIATM sales data for the 12 month period ending April 2019, the EVOCLIN Foam, 1% market achieved annual sales of approximately $17.0 million.
The company’s current portfolio consists of 156 products authorized for distribution in the U.S. marketplace and 59 ANDA’s pending approval with the USFDA. In addition, the company continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.
Glenmark Pharmaceuticals is a global pharmaceutical company. The company is engaged in the development of new chemical entities (NCEs) and new biological entities (NBEs). Its segments are India, United States, Latin America, Europe and Rest of the World (ROW).
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1673.90 |
| Dr. Reddys Lab | 1237.60 |
| Cipla | 1237.10 |
| Zydus Lifesciences | 941.00 |
| Lupin | 2328.40 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: